<b>Peripheral Blood:</b> 2-5 mL in sodium heparin tube. EDTA tube is acceptable.<br>
<b>Fresh, Unfixed Tissue:</b> Tissue in RPMI.<br>
<b>Bone Marrow/Peripheral Blood Smear or Fresh Tissue Touch Preparation Slides:</b> Minimum 7 slides, labeled with specimen type.<br>
<b>Fluids:</b> Mix in equal parts with RPMI (specimen volume to RPMI ratio of 1:1).<br>
<b>Fixed Cell Suspension:</b> A client-prepared fixed cell suspension is acceptable if received in 3:1 Methanol:Glacial Acetic Acid.</p>
TCF3/PBX1 (E2A/PBX1) t(1;19)<br>
Trisomy or Tetrasomy 4, 6, 10, 17 (Cen 4, Cen 6, Cen 10, Cen 17)<br>
MYC (8q24)<br>BCR/ABL1/ASS1 t(9;22)<br>
MLL (11q23)<br>
IgH (14q32)<br><br>
Test Customization: Probes may be ordered separately, except that Centromeres 4 and 17 are paired, as are Centromeres 6 and 10. CDKN2A (p16) deletion testing is available to be ordered separately.<br><br>
STAT Processing (upon request): Available for BCR/ABL1/ASS1 t(9;22). Include "STAT" along with the requesting physician's name and contact information for expedited results.</p>
The ALL Adult FISH Panel is used to detect recurrent chromosome abnormalities in adults with B-cell acute lymphoblastic leukemia (B-ALL) and B lymphoblastic lymphoma (LBL). Identifying specific abnormalities helps predict disease aggressiveness and response to therapy, guiding both risk stratification and treatment decisions.
This panel includes key targets relevant to adult disease biology, including the Philadelphia chromosome (BCR-ABL1) and other translocations and copy number changes linked to prognosis and therapy selection. A positive result for BCR-ABL1, for example, indicates Philadelphia-positive ALL, which can be treated with tyrosine kinase inhibitors (TKIs) (Fielding et al., 2014; Jabbour et al., 2015). Similarly, detecting MYC or MLL rearrangements can signal more aggressive disease and the need for alternative treatment approaches (Arber et al., 2017). Trisomies and tetrasomies of chromosomes 4, 6, 10, and 17 can provide additional prognostic information and influence treatment intensity (Moorman et al., 2007).
This panel is designed specifically for adults and excludes probes for ETV6/RUNX1 t(12;21), which are more common in pediatric ALL (Pui et al., 2011). The insights provided by this panel support both initial diagnosis and ongoing management, helping oncologists tailor therapy to each patient’s genetic profile.
12-24 hours from receipt in the NeoGenomics laboratory